RT Journal Article
SR Electronic
T1 Imaging the Folate Receptor on Cancer Cells with <sup>99m</sup>Tc-Etarfolatide: Properties, Clinical Use, and Future Potential of Folate Receptor Imaging
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 701
OP 704
DO 10.2967/jnumed.113.133074
VO 55
IS 5
A1 Alan H. Maurer
A1 Philip Elsinga
A1 Stefano Fanti
A1 Binh Nguyen
A1 Wim J.G. Oyen
A1 Wolfgang A. Weber
YR 2014
UL http://jnm.snmjournals.org/content/55/5/701.abstract
AB Folate receptor (FR) can be used as a therapeutic target because of its expression on different epithelial cancers, such as ovarian, non–small cell lung, endometrial, and breast cancer. Assessing FR expression in tumors may help to identify patients who can benefit from FR-targeted therapeutics, such as vintafolide and farletuzumab. Different methods exist to detect FR expression. Tissue sampling has limited clinical utility, mainly because it requires an invasive procedure. 99mTc-etarfolatide, a 99mTc-labeled folate conjugate, is in late-phase trials in Europe and the United States. It allows noninvasive, whole-body imaging of the FR. This review focuses on this FR-imaging agent and how it may be used to direct FR-targeted therapy.